Introduction
Increased intraocular pressure (IOP) is a well-known risk factor for development of glaucoma [17] and also for glaucoma progression [14] . IOP is a dynamic parameter, i.e. IOP values and measurements fluctuate during the 24 hours of the day. Fluctuations of IOP have been the subject of many studies, but most describe diurnal patterns of IOP. Maslenikow [21] was one of the first in 1904. Much later, Duke Elder [9] reported that diurnal variation seldom exceeded 5 mmHg in healthy subjects. This finding was confirmed by Drance [7] , who also showed that a majority of untreated glaucoma patients had IOP fluctuations larger than 5 mmHg. At that time increased IOP fluctuations were thought of as an indicator of early glaucoma [8, 18] , although it was also known that IOP fluctuations are proportional to IOP levels [19, 24] , i.e. that patients with higher IOP also have larger IOP variation. Later, De Vivero et al. [6] could not demonstrate higher IOP variation in normaltension glaucoma patients than in normal subjects. Today reports are available in which the effects of IOP level and IOP fluctuations as risk factors for glaucoma and glaucoma progression have been separated. Asrani et al. [2] reported that increased IOP fluctuations, as revealed by diurnal tension curves using home tonometry, increased the risk for glaucoma progression. Only patients with IOP<24 mmHg during follow-up were included in the analysis. In a study by Ishida et al. [16] , results depended upon which criteria for visual field progression were applied. In the study by Daugeline et al. [5] , IOP variability was not an independent risk factor. Both the latter studies included patients with normal-tension glaucoma only.
Effects of IOP fluctuations on visual fields have also been studied in glaucoma patients with elevated pressures. Smith [25] found that diurnal fluctuations were as large in patients with elevated IOP without field loss as in glaucoma patients with field defects, while Bergeå et al. [4] reported that glaucoma in patients with smaller IOP variations progressed less often than in those with larger variations. In a longitudinal study of patients with ocular hypertension Gonzales et al. [10] reported that increased IOP variation at one baseline diurnal tension curve was a risk factor for development of glaucomatous field defects using manual perimetry.
A couple of studies reporting IOP fluctuations to be an independent risk for glaucoma and glaucoma progression [2, 4] have analysed IOP measurements obtained at different times, e.g. baseline IOP fluctuations and follow-up IOP levels, or vice versa. This approach is not well suited to determine whether IOP fluctuations are an independent risk factor, i.e. whether they predict future risk better than the IOP level itself, e.g. mean IOP.
The alleged proof for IOP fluctuations as an independent risk factor for glaucoma or glaucoma progression is thus rather weak. Despite this, increased diurnal fluctuation is frequently referred to as an important risk factor for glaucoma progression, e.g. in printed and web-based material provided by the drug industry.
Our aim was to study the effect of IOP fluctuations on the incidence of glaucomatous visual field loss in patients with ocular hypertension, who were prospectively followed up with diurnal office-hours tension curves and computerised perimetry every 3 months for up to 10 years, and subsequently followed up for a maximum of 17 years as clinical patients. We wanted to separate the effects of IOP variations and IOP level, in order to study whether IOP fluctuations were an independent risk factor.
Subjects and methods
The prospective study Ninety patients with ocular hypertension were included in the prospective Malmö Ocular Hypertension study. Detailed inclusion criteria have been published before [3, 11] , but briefly patients had to have an untreated IOP ≥22 mmHg, defined as the mean of three measurements with the Goldmann tonometer at, 0800, 1130 and 1530 hours, and normal visual fields. Prior to inclusion, visual fields were tested with static threshold computerised perimetry with the Competer perimeter [13] and with peripheral and nasal midperipheral kinetic testing on the Goldmann perimeter. At least one additional risk factor was required for inclusion: suspect disc topography or disc haemorrhage, positive family history of glaucoma, pseudo-exfoliation or pigment dispersion syndrome, diabetes, or mean IOP of ≥27 mmHg on the baseline diurnal tension curve.
Patients were recruited consecutively between 1981 and 1987 and gave informed consent to participate. The tenets of the declaration of Helsinki were followed and the study was approved by the Ethics Committee of the Medical Faculty of Lund University.
The study was designed as a randomised, prospective, double-masked trial comparing topical timolol treatment with placebo treatment. Patients were prospectively followed up every 3 months for 10 years or until they reached the outcome, which was development of reproducible glaucomatous visual field loss. Some patients also left the prospective study because of mean IOP ≥35 mmHg, appearance of nonglaucomatous visual field defects caused by neurological or retinal conditions, dense cataract, adverse reactions, systemic β-blocker treatment, serious illness, or because they wished to withdraw. Detailed information about attrition has been published [11] . These patients were included in the retrospective analysis.
All patients underwent diurnal Goldmann tonometry (at 0800, 1130 and 1530 hours), computerised threshold perimetry with the Competer perimeter, disc photography and a general eye examination at each visit every 3 months while being followed up in the prospective part of the study. During this part 22 patients developed visual field defects, defined as reproducible clusters of depressed test point locations as compared to the mode value of the test. Seven patients died and three were lost to follow-up.
The retrospective follow-up
After leaving the prospective part of the study, all living patients but the three lost for follow-up during the prospective part were still followed up at our department.
For the purpose of this paper, all available poststudy patient records were searched except those of patients who had developed reproducible glaucomatous field loss, had been lost to follow-up, or had died during the prospective part of this study. Throughout the poststudy phase most patients were changed from computerised threshold perimetry on the Competer perimeter to the 30-2 Full Threshold test of the Humphrey Field Analyzer 640 (Carl Zeiss Meditech, Dublin, CA, USA). Thus, those patients who developed glaucoma field loss, defined as a reproducible cluster of significantly depressed points in pattern deviation probability maps [15] , during the retrospective follow-up were examined with the Full Threshold program of the Humphrey Field Analyzer.
IOP parameters
All IOP data included in our analyses were those collected using diurnal tension curves during the prospective part of the study. Individual levels of IOP were computed in different ways:
1. As the mean of all measurements 2. As the mean of the maximum IOP measurement of each diurnal tension curve 3. As the mean of a randomly chosen value of the three IOP values of each tension curve Individual IOP variation was also computed in different ways:
1. As the mean of the range of each diurnal tension curve 2. As the maximum range in all tension curves 3. As the difference between the lowest and highest IOP values measured during the whole prospective part of the study All analyses were based on patients rather than eyes. When both eyes of a patient were eligible, the first eye to reach the outcome was included in the analyses. When visual field remained normal, one eye was randomly selected.
Statistical analyses
Univariate Cox regression analyses were performed to evaluate the different parameters of IOP levels and IOP variability as risk factors for developing glaucomatous visual field defects. A multivariate Cox regression analysis was performed to evaluate the simultaneous effect of IOP fluctuations and IOP level. All Cox analyses were performed using treatment group, timolol or placebo, as a stratification variable, i.e. effects of treatment on IOP were controlled for.
Results

Fifty
Using univariate analyses, all parameters describing IOP level came out as highly significant risk factors ( Table 1) . The risk for developing glaucoma increased by slightly more than 20% for each millimeter of mercury of pressure. The mean IOP of all measurements showed somewhat higher risk than the mean of the maximum IOP or that of a randomly chosen IOP value from every tension curve.
When analysing IOP fluctuations using univariate models, the mean of the daily range came out as an almost significant risk factor (p=0.063) ( Table 2 ). The highest daily range and the highest total range were not associated with any increase of risk.
When applying a multivariate analysis including both IOP level and IOP fluctuations, only mean IOP came out as a significant risk. Thus, the effect of IOP fluctuations was nonsignificant (p=0.49) when separated from IOP level using multivariate analysis (Table 3) .
Discussion
In this group of patients with high-risk ocular hypertension, IOP fluctuations were not an independent risk factor for glaucoma development. Mean IOP was a strong and highly significant risk factor both in uni-and multivariate analyses, while IOP fluctuations were almost significant but only when IOP level not was taken into account. These results could be explained by the dependence of IOP fluctuations on IOP level; IOP fluctuations increased by 0.17 mmHg for each 1 mmHg increase in IOP level (linear regression analysis p<0.0001). Thus, IOP fluctuations were proportional to mean IOP (Fig. 1) .
Gonzales et al. [10] found that IOP fluctuations were a significant risk factor for glaucomatous visual field defects in patients with ocular hypertension. They compared de- velopment of field loss in two groups of patients: one with IOP fluctuations >5 mmHg and another with such fluctuations ≤5 mmHg at a baseline tension curve. Thus, the IOP level itself was not considered at all. Our univariate analysis also suggested that increased IOP fluctuations may be a risk factor, but when taking IOP level into account IOP fluctuations lost importance totally.
Most studies have looked at IOP fluctuations as a risk factor for progression of glaucomatous visual field loss. Such progression may be more difficult to estimate than onset of glaucomatous damage because of the much greater perimetric test-retest variability in diseased eyes than in normal ones. Different criteria for field progression could then yield different study results. Thus, Ishida et al. [16] found that increased IOP fluctuation was a risk for visual field progression when defining progression as pointwise deterioration of threshold values, but not when defining progression as deterioration of the global mean deviation values.
In our study all patients were tested with the threshold program of the computerised static Competer perimeter during the prospective phase. During the clinical followup the patients switched to the 30-2 Full Threshold program of the Humphrey Field Analyzer. This means that the patients who developed glaucoma during the prospective part of the study were diagnosed using a different instrument than those who developed reproducible field loss during the retrospective follow-up part. We do not believe, however, that there were any important differences between the two instruments in their ability to identify repeatable glaucomatous field loss. Some early studies reported similar sensitivities and specificities between the Competer and Octopus perimeters (Haag-Streit, Switzerland), and between the Octopus and Humphrey Field Analyzer perimeters [12, 22] .
Asrani et al. [2] found that IOP fluctuation, as measured with self-tonometry at home, was a significant risk factor for progression independent of IOP level. This report has often been cited as proof for variability as a risk factor for glaucoma progression. Others have pointed out, however, that the Asrani et al. study lacked well-defined criteria for visual field glaucoma progression, and also doubts have been raised about patients' ability to perform the self-tonometry, making the significance of the results less reliable [26] . Further, the analysis was limited to patients with normal or only slightly increased IOP. More than 60% of the subjects originally included were excluded from the analysis because they showed IOP >24 mmHg once or more during the 5-year follow-up. The conclusions of Asrani and co-workers' study could therefore not be considered as relevant for the large majority of clinical glaucoma patients with increased IOP. The patients included in Asrani et al.'s study were quite different from those included in our study. We included patients with increased IOP only, while such patients were excluded from the analyses in Asrani et al.'s study; hence, there is little similarity between the patients analysed in the present study and those in their paper.
In the study by Bergeå et al. [4] multivariate analyses including several different IOP parameters were performed. Prior to the risk analyses these authors carried out principalcomponent analysis to avoid multicollinearity, i.e. to avoid highly inter-correlated explanatory variables in the same model. This resulted in a number of multivariate regression models including different IOP parameters. Two of them included IOP range, calculated in the same way as our "mean of daily range". In one of these two regression models IOP range was combined with untreated baseline IOP and in the other with IOP change, i.e. treatment effect calculated as the difference between untreated baseline IOP and mean of A recent paper by Nouri-Mahdavi et al. [23] reports that IOP fluctuation, calculated as the standard deviation of single IOP measurements measured at different days during the follow-up of the Advanced Glaucoma Intervention Study and analysed using a multivariate technique, was a significant risk factor for visual field deterioration. Surprisingly, and in contrast with an earlier AGIS report [1] , mean IOP did not increase the risk for field worsening.
The apparent differences between our results and those of several studies discussed above most likely depend on whether both IOP level and IOP variability have been independently analysed in a multivariate way. We should point out that we measured IOP during office hours only. More measurements outside office hours would of course improve estimates of fluctuations, but retention was also important. It is not likely that patients would have stayed for 10 years in the prospective part of the study if we had asked them to come for measurements more than three times per day every 3 months. Bergeå et al. [4] also measured office-hours curves three times per day, while the patients included in the study by Asrani et al. [2] measured their own pressure five times a day, from early morning to bedtime. In this context it could be of interest to mention a more recent study by Liu et al. [20] , where IOP was measured every 2 h during a 24-h period in patients with untreated glaucoma and in age-matched healthy subjects. The authors found that diurnal IOP was higher in the glaucoma eyes, but that the diurnal to nocturnal IOP range was larger in the healthy eyes. This result could be interpreted as showing that high diurnal IOP is a risk for glaucoma, but not large IOP fluctuation.
In summary, in the present study IOP fluctuations were not an independent risk factor for the incidence of glaucomatous visual field loss.
